

10/539234

JC17 Rec'd PCT/PTO 16 JUN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Shirou MAEDA et al. : **Mail Stop: PCT**  
Serial No. NEW : Attorney Docket No. 2005\_0752A  
Filed June 16, 2005 :

NOVEL 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVE  
[Corresponding to PCT/JP2003/016131  
Filed December 16, 2003]

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP2003/016131; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

ATTACHMENT C }

JC17 Rec'd PCT/PTO 16 JUN 2005

**and thus no certification and/or fee is required.**

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**  
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

JC17 Rec'd PCT/PTO 16 JUN 2005

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Shirou MAEDA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 16, 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: June 16, 2005

ATTY DOCKET NO.  
2005\_0752ASERIAL NO.  
NEW

10/539234

APPLICANT  
Shirou MAEDA et al.FILING DATE  
June 16, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,563,988	2/1971	Feichtinger et al.			
	AB	3,287,366	11/1966	Newman et al.			
	AC	5,565,451	10/1996	Peake et al.			
	AD						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE	99/01442	1/1999	WO			
	AF	45-41591	12/1970	JP			X
	AG	00/32580	6/2000	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	R. J. A. Walsh et al., "The Structure Activity Relationship of Antibacterial Substituted 1-Phenyl-4,6-Diamino-1,2-Dihydro-2,2-Dimethyl-s-triazines", Eur. J. Med. Chem., Vol. 12, No. 6, pp. 495-500, November- December 1977.
	AI	M. S. Bartlett et al., "Evaluation of Potent Inhibitors of Dihydrofolate Reductase in a Culture Model for Growth of <i>Pneumocystis carinii</i> ", Antimicrobial Agents and Chemotherapy, pp. 2436-2441, Vol. 39, No. 11, November 1995.
	AJ	L. Chio et al., "Identification of Highly Potent and Selective Inhibitors of <i>Toxoplasma gondii</i> Dihydrofolate Reductase", Antimicrobial Agents and Chemotherapy, Vol. 37, No. 9, pp. 1914-1923, September 1993.
	AK	H. M. Eisa et al., "Synthesis of certain 2-aminoadamantane derivatives as potential antimicrobial agents", Pharmazie, Vol. 46, No. 3, pp. 182-184, 1991.
	AL	H. M. Eisa et al., "Synthesis and Antimicrobial Testing of 2-Amino-4- (p-Fluro-m-Nitroanilino)-6-Substituted-s-Triazines", Pakistan J. Sci. Ind. Res., Vol. 31, No. 7, pp. 474-478, July 1988.
	AM	E. A. Coats et al., "Quantitative Structure-Activity Relationship of Antifolate Inhibition of Bacteria Cell Cultures Resistant and Sensitive to Methotrexate", J. Med. Chem. Vol. 28, No. 12, pp. 1910-1916, 1985.
	AN	B. Testa et al., "Steric and Lipophobic Components of the Hydrophobic Fragmental Constant", Drug Res., Vol. 31, No. 7, pp. 1053-1058, 1981.

EXAMINER

DATE CONSIDERED

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: June 16, 2005

ATTY DOCKET NO.  
2005\_0752ASERIAL NO.  
NEW

10/539234

APPLICANT  
Shirou MAEDA et al.FILING DATE  
June 16, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB						
	BC						
	BD						
	BE						
	BF						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BG	C. S. Genther et al., "Antifolate Studies. Activities of 40 Potential Antimalarial Compounds against Sensitive and Chlorguanide Triazine Resistant Strains of Folate-Requiring Bacteria and <i>Escherichia coli</i> ", Journal of Medicinal Chemistry, Vol. 20, No. 2, pp. 237-243, 1977.
	BH	B. R. Baker, "Differential Binding to the Hydrophobic Bonding Region of T <sub>2</sub> Phage Induced, <i>Escherichia coli</i> B, and Pigeon Liver Dihydrofolic Reductases <sup>1,2</sup> ", Journal of Medicinal Chemistry, Vol. 10, No. 5, pp. 912-917, September 1967.
	BI	T. Seo et al., "Syntheses and Properties of Polyguanamine from Diester and Bisbiguanide", Nippon Kagaku Kaishi, No. 12, pp. 2419-2424, 1974, in Japanese language with English abstract.
	BJ	A. Rosowsky et al., "Structure-Activity and Structure-Selectivity Studies on Diaminoquinazolines and other Inhibitors of <i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> Dihydrofolate Reductase", Antimicrobial Agents and Chemotherapy, Vol. 39, No. 1, pp. 79-86, January 1995.
	BK	W. R. Turner et al., "Novel Bis[1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamines] as Antitrypanosomal Agents <sup>1,2</sup> ", J. Med. Chem., Vol. 28, No. 11, pp. 1728-1740, 1985.
	BL	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.